Avanzanite secures €32m Series A funding
Dutch Avanzanite Biosciences NV has secured €32 m in a Series A financing round from MVM Partners to scale orphan drug commercialisation across Europe.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1436 entries already.
Entries by Thomas Gabrielczyk
Millions Flow Into Captain T Cell as Berlin’s Cell Therapy Scene Defies the Gloom
/in News/by Thomas GabrielczykThe company Captain T Cell, spin-out from Max-Delbrück center in Berlin, now has a total of €20 million in funding and grants to push forward its novel cell therapies for solid tumours. New backers include Springboard Health Angels, Pluton Asset Holding, Sintra Limited and the Technologiegründerfonds Sachsen, joining the existing investor base. The new tennant in Bayer´s Co.Lab in Berlin City does starts with positive vibes.
MitoRx Therapeutics advances next-generation obesity therapy
/in News/by Thomas GabrielczykMitoRx Therapeutics Ltd has raised £5.5m in a seed financing to advance Myo‑004, a small molecule mitochondrial-targeted obesity therapy enabling fat loss while preserving lean muscle mass.
Sofinnova Partners surpasses target with €650m fund to back up early-stage biotech
/in News/by Thomas GabrielczykSofinnova Partners has closed its new investment fund, Capital XI, at €650m, far exceeding its original target. The early-stage biotech and medtech-focused fund will invest mostly in Series A, but also seed financings of companies, including oncology, inflammation and immunology, CNS, and cardio-metabolic diseases.
Medicxi announces new €500m biotech investment fund
/in News/by Thomas GabrielczykVC specialist Medicxi has closed its oversubscribed €500m Fund V to support existing biopharmaceutical developers, and creating new companies across all development stages.
Virometix: US$15m for Synthetic Vaccines
/in News/by Thomas GabrielczykSwiss biotech Virometix has raised US$15m in fresh funding to accelerate development of its lead pneumococcal vaccine candidate and advance its next-generation synthetic vaccine platform.
Scripta Therapeutics raises $12m to flip the script on drug discovery
/in News/by Thomas GabrielczykOxford-based techbio startup Scripta Therapeutics has emerged from stealth with a biology-first platform targeting the master regulators of disease.
AZ’s baxdrostat mets endpoint in resistant hypertension
/in News/by Thomas GabrielczykAstraZeneca’s baxdrostat cuts 24-hour systolic BP by 14mmHg in resistant hypertension, offering a novel mechanism and major market potential.
AstraZeneca bolsters obesity portfolio with muscle‑preserving buy
/in News/by Thomas GabrielczykAstraZeneca plc acquires SixPeaks Bio Inc to target muscle‑preserving obesity therapies, boosting its pipeline in a US$30 bn fast-growing weight-loss market.
Breakthrough study reveals stability key for mRNA
/in News/by Thomas GabrielczykA landmark discovery by a team of South Korean scientists could transform the way RNA-based vaccines and therapeutics are developed and produced. Researchers led jointly by Professor V. Narry Kim and Professor Jin-Hong Kim have identified a series of viral RNA motifs that make conventional messenger RNA (mRNA) far more stable and efficient, potentially revolutionising RNA drug manufacturing.